Abstracts Archive - Page 1359 of 2607 - ACR Meeting Abstracts

Abstract Number: 2592 • 2018 ACR/ARHP Annual Meeting
Real-World Use of Secukinumab in Psoriatic Arthritis: First Year Data from the Czech National Registry
Herman F Mann¹, Jakub Zavada², Lucie Nekvindová³, Zlatuse Kristkova³, Pavel Horák⁴, Jiri Vencovsky¹ and Karel Pavelka², ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Czech Republic, Prague 2, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ³Institute of Biostatistics and Analyses, Ltd., spinoff company of Masaryk University, Brno, Czech Republic, ⁴IIIrd Department of internal Medicine, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
Background/Purpose: Until recently, inhibitors of TNF (TNFi) had been the only bDMARD treatment option for patients with psoriatic arthritis (PsA). This situation changed when anti-interleukin-17A…
Abstract Number: 2593 • 2018 ACR/ARHP Annual Meeting
Similar Efficacy and Safety of Biosimilar Candidate IBI303 and Reference Products of Adalimumab in Patients with Ankylosing Spondylitis : Results from a Randomized, Double-Blind, Phase III Study
Xu Huji¹, Li Zhijun², Wu Jian³, Xing Qian⁴, Guixiu Shi⁵, Li Juan⁶, Liu Xu⁷, Lijun Wu⁸, Li Xiaomei⁹, Tan Wenfeng¹⁰, Dongyi He¹¹, Bi Liqi¹², Li Hongbin¹³, Xiao Zhengyu¹⁴, Shuai Zongwen¹⁵, Li Xiaoxia¹⁶, Wang Yongfu¹⁷, Luo Li¹⁸, Zheng Yi¹⁹, Xiao Weiguo²⁰, Zhou Hui²¹, Lu Yushan²¹, Zheng Shirui²¹ and Wang Xiong²¹, ¹Shanghai Changzheng Hospital, Shanghai, China, ²The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, ³The First Affiliated Hospital of Soochow University, Suzhou, China, ⁴Qingdao municipal hospital, Qingdao, China, ⁵The First Affiliated Hospital of Xiamen University, Xiamen, China, ⁶Nanfang Hospital, Southern Medical University, Guangzhou, China, ⁷Peking University People’s Hospitalv, Beijing, China, ⁸People's Hospital of Xinjiang Uygur Autonomous Region, Wulumuqi, China, ⁹Anhui Provincial Hospital, Hefei, China, ¹⁰Jiangsu Province Hospital, Nanjing, China, ¹¹Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China, ¹²China-Japan Friendship Hospital, Changchun, China, ¹³The Affiliated Hospital of Inner Mongolia Medical University, Huhehaote, China, ¹⁴The First Affiliated Hospital of Shantou University Medical College, Shantou, China, ¹⁵The First Affiliated Hospital of Anhui Medical University, Hefei, China, ¹⁶Xuanwu Hospital Capital Medical University, Beijing, China, ¹⁷The First Affiliated Hospital of Baotou Medical College of Inner Mongolia University of Science & Technology, Baotou, China, ¹⁸The First Affiliated Hospital of XinJiang Medical University, Wulumuqi, China, ¹⁹Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China, ²⁰The First Hospital of China Medical University, Shenyang, China, ²¹Innovent Biologics (Suzhou) Co. Ltd, Shanghai, China
Background/Purpose: IBI303, an injection of recombinant human anti-tumor necrosis factor-α monoclonal antibody, is adalimumab biosimilar candidate. Physicochemical properties assessment and non-clinical studies showed the structure,…
Abstract Number: 2594 • 2018 ACR/ARHP Annual Meeting
Median Time to Pain Improvement in Patients with Psoriatic Arthritis Treated with Tofacitinib
Kurt de Vlam¹, Alexis Ogdie², Andrew G Bushmakin³, Joseph C Cappelleri³, Roy Fleischmann⁴, Peter C. Taylor⁵, Valderilio F Azevedo⁶, Lara Fallon⁷, Anna Maniccia⁸, John Woolcott⁹ and Philip J. Mease¹⁰, ¹UZ Leuven, Leuven, Belgium, ²University of Pennsylvania, Philadelphia, PA, ³Pfizer Inc, Groton, CT, ⁴University of Texas Southwestern Medical Center, Dallas, TX, ⁵University of Oxford, Oxford, United Kingdom, ⁶Universidade Federal do Paraná, Curitiba, Brazil, ⁷Pfizer Canada, Montreal, QC, Canada, ⁸Pfizer Inc, New York, NY, ⁹Pfizer Inc, Collegeville, PA, ¹⁰Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Pain is a core domain of psoriatic arthritis (PsA).1 Rapid, sustained pain reduction is a priority for patients (pts) and physicians when choosing treatment.…
Abstract Number: 2595 • 2018 ACR/ARHP Annual Meeting
Golimumab Improves Socio- and Health Economic Parameters in Patients with RA, Psa and As: Real World-Data from a Non-Interventional Clinical Study in Germany
Klaus Krüger¹, Gerd R. Burmester², Siegfried Wassenberg³, Valeria Biermann⁴ and Matthias H. Thomas⁵, ¹Medical Centre of Rheumatology, Munich, Germany, ²Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ³Rheumazentrum Ratingen, Ratingen, Germany, ⁴Lehrstuhl für Gesundheitsmanagement, Universität Erlangen-Nürnberg, Nürnberg, Germany, ⁵Medical Affairs, MSD Sharp & Dohme GmbH, Haar, Germany
Background/Purpose: Golimumab (GLM) has shown its efficacy and safety in various clinical trials. Data from socio- and health economic parameters and costs in daily clinical…
Abstract Number: 2596 • 2018 ACR/ARHP Annual Meeting
Real-World Long-Term Effectiveness of Switching between Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis Patients from the Rheumatic Diseases Portuguese Register
Elsa Vieira-Sousa^1,2, Mónica Eusébio³, Pedro Ávila-Ribeiro^1,2, Nikita Khmelinskii^1,2, Ana Rita Machado^1,2, Teresa Martins-Rocha^4,5, Miguel Bernardes^4,5, Daniela Santos Faria⁶, Joana Leite Silva⁶, Helena Santos⁷, Cláudia Miguel⁷, Pedro Carvalho^8,9, Tiago Costa¹⁰, Lídia Teixeira¹¹, Tiago Meirinhos¹², Patrícia Nero¹³ and Maria José Santos^11,14, ¹Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal, Lisboa, Portugal, ²Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisboa, Portugal, Lisboa, Portugal, ³Sociedade Portuguesa de Reumatologia, Lisboa, Portugal, LIsboa, Portugal, ⁴Serviços de Reumatologia do Centro Hospitalar São João do Porto, Porto, Portugal, Porto, Portugal, ⁵Faculdade de Medicina da Universidade do Porto (FMUP), Porto, Portugal, Porto, Portugal, ⁶Serviço de Reumatologia da Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, Ponte de Lima, Portugal, ⁷Instituto Português de Reumatologia Lisboa, Portugal, Lisboa, Portugal, ⁸Serviço de Reumatologia, Hospitais Universitários de Coimbra, Coimbra, Portugal, Coimbra, Portugal, ⁹Serviço de Reumatologia, Centro Hospitalar e Universitário do Algarve, Faro, Portugal, Faro, Portugal, ¹⁰Serviço de Reumatologia do Hospital Egas Moniz, Lisboa, Portugal, Lisboa, Portugal, ¹¹Serviço de Reumatologia do Hospital Garcia de Orta, Almada, Portugal, Almada, Portugal, ¹²Serviço de Reumatologia, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, Aveiro, Portugal, ¹³Hospital CUF Descobertas, Lisboa, Portugal, Lisboa, Portugal, ¹⁴Sociedade Portuguesa de Reumatologia, Lisboa, Portugal, Lisboa, Portugal
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) lead to a dramatic improvement in the management of psoriatic arthritis (PsA). Nevertheless, a significant proportion of patients…
Abstract Number: 2597 • 2018 ACR/ARHP Annual Meeting
The Effect of Biologic Disease-Modifying Antirheumatic Drugs in Patient Reported Outcomes in Axial Spondyloarthritis; A Systematic Literature Review and a Call for Action
Santiago Rodrigues Manica^1,2, Joana Leite Silva³, Ana Rita Machado⁴, Constança Coelho⁵, Joana Duarte⁶, Elsa Vieira-Sousa⁷, José Tavares Costa⁸ and Fernando Pimentel-Santos^1,2, ¹CEDOC, NOVA Medical School, Lisbon, Portugal, ²Rheumatology, Hospital de Egas Moniz - Centro Hospitalar Lisboa Ocidental, EPE, Lisbon, Portugal, ³Serviço de Reumatologia da Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, Ponte de Lima, Portugal, ⁴Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal, ⁵Genetics Laboratory, Institute of Environmental Health, Lisbon School of Medicine, University of Lisbon, Lisbon, Portugal, ⁶Medical Department, Novartis Pharma, Pharmaceutical products, Oeiras, Portugal, ⁷Rheumatology Department, CAML, Lisbon, Portugal, Lisbon, Portugal, ⁸Rheumatology Department, ULSAM, Ponte de Lima, Portugal, Ponte de Lima, Portugal
Background/Purpose: Patient reported outcomes (PROs) have gained relevance in the evaluation of axial SpA (axSpA), as they convey a more objective patient perspective. The concept…
Abstract Number: 2598 • 2018 ACR/ARHP Annual Meeting
Efficacy of Anti-Tumor Necrosis Factor (TNF) Alpha Therapy, in Patients with Spondylarthritis in the University Center of Rouen in France, Divived to the Berlin Algorithm Modified By the Assessement Spondylarthritis Group: A Ten Years Retrospective Study
Christelle Princivil¹, thierry Lequerre², Didier Alcaix³ and Olivier Vittecoq⁴, ¹Jacques Monod hospital center, 76290 Montivilliers, France, montivilliers, France, ²Rheumatology Department, Rouen University Hospital, University of Rouen, 76031 Rouen, France., ROUEN, France, ³Rheumatology Department, Jacques Monod Hospital Center, 76290 Montivilliers, France, montivilliers, France, ⁴INSERM U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen, France
Background/Purpose: Treatments and diagnosis of SpA is a public health problem. The efficacy of anti-TNF alpha treatment is different from one patient to an other.…
Abstract Number: 2599 • 2018 ACR/ARHP Annual Meeting
The Agreement between TNFi Treatment Responses and Fatigue Responses Is Weak to Moderate Suggesting Heterogeneity between Experienced Fatigue and Joint Inflammation: A Danish Population-Based Cohort Study
Tanja Schjødt Jørgensen¹, Marie Skougaard¹, Rebekka L Hansen¹, Christine Ballegaard¹, Philip J. Mease², Vibeke Strand³, Lene Dreyer⁴ and Lars Erik Kristensen¹, ¹The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen F, Denmark, ²Swedish Medical Center and University of Washington, Seattle, WA, ³Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁴Departments of Rheumatology and Clinical Medicine, Aalborg University Hospital and Aalborg University., Hellerup, Denmark
Background/Purpose: Despite better control of inflammation, e.g. with biological treatments, some patients with psoriatic arthritic (PsA) continue to cite fatigue as one of the most…
Abstract Number: 2600 • 2018 ACR/ARHP Annual Meeting
Clinically Meaningful Improvement in Health-Related Quality of Life and the Association with Disease Activity in Psoriatic Arthritis after Treatment with Guselkumab: Results from a Randomized Placebo-Controlled Phase II Clinical Trial
Laure Gossec¹, Bruce Kirkham², Proton Rahman³, Philip Helliwell⁴, Alice B Gottlieb⁵, Wolf-Henning Boehncke⁶ and Chenglong Han⁷, ¹Rheumatology Department, Hôpital Pitié Salpêtrière, Paris 06 University, Paris, France, ²Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ³Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, ⁴LIMM, Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ⁵Department of Dermatology, New York Medical College, Metropolitan Hospital, New York, NY, ⁶Department of Dermatology and Venereology, Geneva University Hospital, Geneva, Switzerland, ⁷Janssen Global Services, LLC, Malvern, PA
Background/Purpose: To evaluate the effect of guselkumab (GUS) on Health-Related Quality of Life (HRQOL) and correlate changes of HRQOL and disease activity in patients with…
Abstract Number: 2601 • 2018 ACR/ARHP Annual Meeting
Nonsteroidal Anti-Inflammatory Drugs Attenuate Active Inflammatory Sacroiliac Joint Lesions in Patients with Early Axial Spondyloarthritis
Hong-Ki Min¹, Hyonjoung Cho² and Sung-Hwan Park³, ¹Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Armed Forces Capital hospital, Armed Forces Medical Command, Seongnam, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)
Background/Purpose: The purpose of the present study was to examine the therapeutic effect of NSAIDs on active inflammatory lesions (bone marrow oedema [BMO]) in the…
Abstract Number: 2602 • 2018 ACR/ARHP Annual Meeting
Evolution of Patient Characteristics in the Era of Biological Treatment of Psoriatic Arthritis: 18-Year Belgian Experience from Leuven Spondyloarthritis Biologics Cohort (BioSPAR)
Alla Ishchenko¹, Rik Lories² and Kurt de Vlam³, ¹Rheumatology, KU Leuven, Skeletal Biology and Engineering Research Center & University Hospitals Leuven, Leuven, Belgium, ²Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium, ³UZ Leuven, Leuven, Belgium
Background/Purpose: Biologicals revolutionized the management of PsA. Since the introduction of the first TNF inhibitor (TNFi) in the early 2000s, therapeutic options for PsA are…
Abstract Number: 2603 • 2018 ACR/ARHP Annual Meeting
Efficacy of Tildrakizumab in Etanercept Partial Responders or Nonresponders
Jeffrey Crowley¹, Kim A Papp², Chih-ho Hong³, Jeff Parno⁴, Alan M Mendelsohn⁴, Qing Li⁵ and Nicole Cichanowitz⁵, ¹Bakersfield Dermatology, Bakersfield, CA, ²Probity Medical Research, Waterloo, ON, Canada, ³University of British Columbia, Department of Dermatology and Skin Science and Probity Medical Research, Surrey, BC, Canada, ⁴Sun Pharmaceutical Industries, Inc., Princeton, NJ, ⁵Merck & Co., Inc., Kenilworth, NJ
Background/Purpose: Etanercept (ETN), an anti-TNF medication, was among the first biologics approved for psoriasis. Additional psoriasis medications that have been developed, or are in development,…
Abstract Number: 2604 • 2018 ACR/ARHP Annual Meeting
Incidence of Serious Gastrointestinal Events and Inflammatory Bowel Disease Among Tildrakizumab-Treated Patients with Moderate to Severe Plaque Psoriasis: Data from 3 Large Randomized Clinical Trials
Melinda Gooderham¹, Boni E. Elewski², David M. Pariser³, Howard Sofen⁴, Alan M Mendelsohn⁵, Nicole Cichanowitz⁶ and Qing Li⁶, ¹Probity Medical Research, and Skin Center for Dermatololgy, Waterloo, and Peterborough, ON, Canada, ²University of Alabama at Birmingham, Birmingham, AL, ³Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, VA, ⁴Ronald Reagan UCLA Medical Center, Department of Medicine (Dermatology) UCLA, Los Angeles, CA, ⁵Sun Pharmaceutical Industries, Inc., Princeton, NJ, ⁶Merck & Co., Inc., Kenilworth, NJ
Background/Purpose: Tildrakizumab (TIL), a high-affinity, humanized, immunoglobulin G1κ, anti–interleukin-23p19 monoclonal antibody, has demonstrated efficacy in the treatment of chronic plaque psoriasis.1,2 Here, we evaluate the…
Abstract Number: 2605 • 2018 ACR/ARHP Annual Meeting
Drug Retention and Response Rates of TNFi Treatment in 13,170 Patients with Psoriatic Arthritis Treated in Routine Care – Pooled Data from the Eurospa Research Network Collaboration
Cecilie Heegaard Brahe¹, Lykke Midtbøll Ørnbjerg¹, Lennart Jacobsson², Michael J. Nissen³, Eirik K Kristianslund⁴, Maria José Santos⁵, Kari Eklund⁶, Ziga Rotar⁷, Björn Gudbjornsson⁸, Fatos Onen⁹, Catalin Codreanu¹⁰, Ulf Lindström¹¹, Cem Gabay³, Tore Kvien⁴, Anabela Barcelos⁵, Kalle Aaltonen⁶, Matija Tomšič⁷, Thorvardur Love⁸, Gerçek Can⁹, Ruxandra Ionescu¹⁰, Anne Gitte Loft¹, Herman F Mann¹², Karel Pavelka¹², Marleen van de Sande¹³, Irene van der Horst-Bruinsma¹⁴, Juan J. Gomez-Reino¹⁵, Carlos Sánchez-Piedra¹⁶, Gary J Macfarlane¹⁷, Florenzo Iannone¹⁸, Lise Hyldstrup¹, Niels Steen Krogh¹⁹, Mikkel Østergaard¹ and Merete Lund Hetland¹, ¹DANBIO, EuroSpA Research Collaboration Network, Coordinating Centre, Copenhagen, Denmark, ²ARTIS, EuroSpA Research Collaboration Network, Gothenburg, Sweden, ³SCQM, EuroSpA Research Collaboration Network, Geneva, Switzerland, ⁴NOR-DMARD, EuroSpA Research Collaboration Network, Oslo, Norway, ⁵Reuma.pt, EuroSpA Research Collaboration Network, Lisbon, Portugal, ⁶ROB-FIN, EuroSpA Research Collaboration Network, Helsinki, Finland, ⁷biorx.si, EuroSpA Research Collaboration Network, Ljubljana, Slovenia, ⁸ICEBIO, EuroSpA Research Collaboration Network, Reykjavik, Iceland, ⁹TURKBIO, EuroSpA Research Collaboration Network, Izmir, Turkey, ¹⁰RRBR, EuroSpA Research Collaboration Network, Bucharest, Romania, ¹¹ARTIS, EuroSpA Research Collaboration Network, Stockholm, Sweden, ¹²ATTRA, EuroSpA Research Collaboration Network, Prague, Czech Republic, ¹³ARC, EuroSpA Research Collaboration Network, Amsterdam, Netherlands, ¹⁴ARC, EuroSpA Research Collaboration Network, Harleem, Netherlands, ¹⁵BIOBADASER, EuroSpA Research Collaboration Network, Santiago, Spain, ¹⁶BIOBASADER, EuroSpA Research Collaboration Network, Santiago, Spain, ¹⁷BSRBR-AS, EuroSpA Research Collaboration Network, Aberdeen, United Kingdom, ¹⁸GISEA, EuroSpA Research Collaboration Network, Bari, Italy, ¹⁹ZiteLab ApS, Copenhagen, Denmark
Drug retention and response rates of TNFi treatment in 13,170 patients with psoriatic arthritis treated in routine care – pooled data from the EuroSpA Research…
Abstract Number: 2606 • 2018 ACR/ARHP Annual Meeting
Long-Term Inhibition of Radiographic Progression with Originator Adalimumab in Patients with Moderate to Severe Psoriatic Arthritis with or without Radiographic Damage at Baseline
Laura C. Coates¹, Philip J. Mease², Kun Chen³, Maja Hojnik⁴, Wendell Valdecantos³, Pranav Sheth⁵, Daniel Aletaha⁶ and Fabiana Ganz⁷, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Swedish Medical Centre and University of Washington, Seattle, WA, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie, Ljubljana, Slovenia, ⁵Group Health Associates, Trihealth, Cincinnati, OH, ⁶Medical University of Vienna, Vienna, Austria, ⁷AbbVie AG, Baar, Switzerland
Background/Purpose: Adalimumab (ADA) inhibited radiographic progression in patients (pts) with moderate to severe PsA in the ADEPT study and its open label extension (OLE). These…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].